GMAB Genmab A/S

21.54
+1.32  (+7%)
Previous Close 20.22
Open 20.99
Price To Book 6.82
Market Cap 14,034,726,901
Shares 651,565,780
Volume 726,830
Short Ratio
Av. Daily Volume 498,962
Stock charts supplied by TradingView

NewsSee all news

  1. Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

    NEW YORK, March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand

  2. Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    NEW YORK, March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand

  3. International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    NEW YORK, March 16, 2020 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations

  4. International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    NEW YORK, March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from

  5. Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer

    Company Announcement Copenhagen, Denmark; March 10, 2020 – Genmab A/S (NASDAQ:GMAB) announced today that Anthony Mancini will join the company as Executive Vice President and Chief Operating Officer, effective March 23,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1H 2020.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
PDUFA date under priority review June 2020.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
FDA Approval announced June 28, 2019.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
sNDA filed January 2020.
KYPROLIS (CANDOR)
Multiple Myeloma
FDA Approval announced September 26, 2019.
Daratumumab + VTD
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Phase 1/2 initial data presented at IASLC 2019 WCLC September 8, 2019.
Enapotamab vedotin
Solid tumors
Phase 1/2 initial data due in 2020.
HexaBody-DR5/DR5
Solid tumors
Phase 1/2 initial data presented at ASH December 9, 2019.
GEN3013 (DuoBody-CD3xCD20)
B-cell Lymphoma
Phase 1/2 data update 2H 2020.
BNT311 / GEN1046
Solid tumors

Latest News

  1. Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for On-Demand Viewing

    NEW YORK, March 26, 2020 /CNW/ - Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand

  2. Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    NEW YORK, March 26, 2020 /PRNewswire/ -- Deutsche Bank today announced that the presentations from the March 18th and 19th Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand

  3. International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    NEW YORK, March 16, 2020 /PRNewswire/ -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations

  4. International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020

    NEW YORK, March 10, 2020 /CNW/ - Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on March 18th and 19th, featuring live webcast presentations from

  5. Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer

    Company Announcement Copenhagen, Denmark; March 10, 2020 – Genmab A/S (NASDAQ:GMAB) announced today that Anthony Mancini will join the company as Executive Vice President and Chief Operating Officer, effective March 23,

  6. Genmab Publishes 2019 Annual Report

    Company Announcement Copenhagen, Denmark; February 19, 2020 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2019. Below is a summary of business progress in 2019, financial

  7. Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen

    Company Announcement Net trade sales of DARZALEX in 2019 totaled USD 2,998 millionGenmab to receive milestone payment of USD 150 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 3

  8. Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement DARZALEX® (daratumumab) approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible

  9. ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

    VICTORIA and UTRECHT, The Netherlands, Jan. 9, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery

  10. Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

    Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research termGenmab

  11. CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement CHMP issued positive opinion for DARZALEX® in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible

  12. Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

    Company Announcement Genmab to receive milestone payment of USD 100 Million in DARZALEX collaboration Milestone triggered by sales of DARZALEX reaching USD 2.5 billion in a calendar year Copenhagen, Denmark; December

  13. Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement DARZALEX® approved in Europe in combination with lenalidomide and dexamethasone as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell

  14. David Eatwell to Retire as Chief Financial Officer of Genmab

    Company Announcement David Eatwell has decided to retire on February 29, 2020Anthony Pagano, Senior Vice President Finance and Corporate Development will be promoted to Executive Vice President and CFO, effective

  15. CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Company Announcement CHMP issued a positive opinion for DARZALEX® in combination with lenalidomide and dexamethasone as treatment for newly diagnosed adult patients with multiple myeloma who are ineligible for

  16. Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

    Company Announcement Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 15, 2019 –

  17. Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma

    Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed with multiple myeloma

  18. Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Company Announcement Phase III CANDOR study of daratumumab in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma met the primary endpoint of improvement in progression free

  19. Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS

    Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the 35th Congress of the

  20. Genmab and Tempus Enter into Strategic Collaboration Agreement

    Media Release Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (NASDAQ:GMAB) announced today that it has entered into a strategic collaboration